Condition (MeSH)
Rubinstein-Taybi Syndrome
ClinicalTrials.gov lists 6 trials for Rubinstein-Taybi Syndrome or a narrower condition beneath it. Mirati Therapeutics Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Rubinstein-Taybi Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Rubinstein-Taybi Syndrome trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Rubinstein-Taybi Syndrome trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Rubinstein-Taybi Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 3 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Rubinstein-Taybi Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Mirati Therapeutics Inc. | 1 |
Which serious adverse events do Rubinstein-Taybi Syndrome trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute Respiratory Failure | 6 | 1 |
| Thrombus | 6 | 1 |
Which publications cover Rubinstein-Taybi Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Behavioural Assessment of Social Anxiety and Social Motivation in Fragile X, Cornelia de Lange and Rubinstein-Taybi Syndromes. | Journal of autism and developmental disorders | 2020 | Yes |
| Evaluation of Motor Skills in Children with Rubinstein-Taybi Syndrome. | Journal of autism and developmental disorders | 2017 | Yes |
| Analysis of CBP (CREBBP) gene deletions in Rubinstein-Taybi syndrome patients using real-time quantitative PCR. | Human mutation | 2004 | Yes |
| Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. | Expert opinion on investigational drugs | 2008 | No |
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Rubinstein-Taybi syndrome | Prevalence at birth | 1-9 / 1 000 000 | Netherlands | Not stated | Exact |
| Rubinstein-Taybi syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Rubinstein-Taybi syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Rubinstein-Taybi syndrome | Point prevalence | 1-9 / 100 000 | Netherlands | Not stated | Unspecified |
| Rubinstein-Taybi syndrome | Prevalence at birth | 1-9 / 1 000 000 | Netherlands | Not stated | Unspecified |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Rubinstein-Taybi syndrome | 783 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Rubinstein-Taybi syndrome | 783 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.